OPKO Health (NASDAQ:OPK) Shares Gap Down to $1.41

OPKO Health, Inc. (NASDAQ:OPKGet Free Report)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $1.41, but opened at $1.38. OPKO Health shares last traded at $1.40, with a volume of 198,445 shares trading hands.

Analyst Upgrades and Downgrades

OPK has been the topic of a number of recent research reports. Barrington Research reissued an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a research note on Monday, April 1st. StockNews.com raised OPKO Health to a “sell” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Wednesday, May 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a research note on Monday, April 1st.

Check Out Our Latest Research Report on OPK

OPKO Health Stock Performance

The stock has a 50 day moving average of $1.30 and a 200 day moving average of $1.23. The company has a quick ratio of 1.62, a current ratio of 1.91 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $899.12 million, a price-to-earnings ratio of -3.69 and a beta of 1.76.

OPKO Health (NASDAQ:OPKGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The company had revenue of $173.70 million during the quarter, compared to analyst estimates of $182.99 million. OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. OPKO Health’s revenue was down 26.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.02) earnings per share. As a group, analysts predict that OPKO Health, Inc. will post -0.36 EPS for the current year.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 600,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was acquired at an average cost of $0.93 per share, for a total transaction of $558,000.00. Following the completion of the acquisition, the chief executive officer now owns 209,468,225 shares in the company, valued at approximately $194,805,449.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders acquired 1,863,997 shares of company stock worth $1,776,556. 47.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently added to or reduced their stakes in the business. IPG Investment Advisors LLC bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $30,000. Virtu Financial LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $26,000. River Wealth Advisors LLC bought a new stake in shares of OPKO Health during the third quarter valued at approximately $38,000. SlateStone Wealth LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $31,000. Finally, Northstar Group Inc. bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $42,000. 64.63% of the stock is currently owned by institutional investors.

About OPKO Health

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Read More

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.